Cargando…
PARP1 Inhibitors: antitumor drug design
The poly (ADP-ribose) polymerase 1 (PARP1) enzyme is one of the promising molecular targets for the discovery of antitumor drugs. PARP1 is a common nuclear protein (1–2 million molecules per cell) serving as a “sensor” for DNA strand breaks. Increased PARP1 expression is sometimes observed in melano...
Autores principales: | Malyuchenko, N. V., Kotova, E. Yu., Kulaeva, O. I., Kirpichnikov, M. P., Studitskiy, V. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
A.I. Gordeyev
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610162/ https://www.ncbi.nlm.nih.gov/pubmed/26483957 |
Ejemplares similares
-
Mechanisms of Nucleosome Reorganization by PARP1
por: Maluchenko, Natalya V., et al.
Publicado: (2021) -
Design, synthesis and in silico studies of new quinazolinone derivatives as antitumor PARP-1 inhibitors
por: Ramadan, Sayed K., et al.
Publicado: (2020) -
Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3
por: Sherstyuk, Yuliya V., et al.
Publicado: (2019) -
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017) -
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)